Inhibition of Myelin-Cleaving Poteolytic Activities by Interferon-Beta in Rat Astrocyte Cultures. Comparative Analysis between Gelatinases and Calpain-II

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Latronico, Tiziana ^a   Branà, Maria Teresa ^a   Gramegna, Pasqua ^a   Fasano, Anna ^a   Di Bari, Gaetano ^a   Liuzzi, Grazia Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CALPAIN 2; CALPASTATIN; GELATINASE A; GELATINASE B; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYELIN BASIC PROTEIN; PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CALPAIN 2 GENE; CALPASTATIN GENE; CELL ACTIVATION; CELL LYSATE; COMPARATIVE STUDY; CONTROLLED STUDY; GELATINASE A GENE; GELATINASE B GENE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ANALYSIS; INHIBITION KINETICS; NERVE CELL CULTURE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE 1 GENE; TISSUE INHIBITOR OF METALLOPROTEINASE 2 GENE; ZYMOGRAPHY;

ANIMALS; ASTROCYTES; CALCIUM-BINDING PROTEINS; CALPAIN; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SPACE; GENE EXPRESSION; INTERFERON-BETA; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYELIN BASIC PROTEIN; MYELIN SHEATH; PRIMARY CELL CULTURE; PROTEASE INHIBITORS; RATS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84873504327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049656     Document Type: Article

References (43)

1. Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM, (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci 259: 79-84.
2. Shields DC, Schaecher KE, Saido TC, Banik NL, (1999a) A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci U S A 96: 11486-11491.
3. Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, et al. (2001) Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 124: 1978-1988.
4. Hassen GW, Feliberti J, Kesner L, Stracher A, Mokhtarian F, (2006) A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 180: 135-146.
5. Shields DC, Tyor WR, Deibler GE, Hogan EL, Banik NL, (1998) Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 95: 5768-5772.
6. Deshpande RV, Goust JM, Hogan EL, Banik NL, (1995) Calpain secreted by activated human lymphoid cells degrades myelin. J Neurosci Res 42: 259-265.
7. Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM, (2006) Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol 111: 289-299.
8. Schaecher K, Rocchini A, Dinkins J, Matzelle DD, Banik NL, (2002) Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. J Neuroimmunol 129: 1-9.
9. Shields DC, Banik NL, (1999) Pathophysiological role of calpain in experimental demyelination. J Neurosci Res 55: 533-541.
10. Bartus RT, Elliott PJ, Hayward NJ, Dean RL, Harbeson S, et al. (1995) Calpain as a novel target for treating acute neurodegenerative disorders. Neurol Res 17: 249-258.
11. Rosenberg GA, (2002) Matrix metalloproteinases in neuroinflammation. Glia 39: 279-291.
12. Opdenakker G, Nelissen I, Van Damme J, (2003) Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2: 747-756.
13. Steinman L, Gijbels K (1994) Gelatinase B producing cells in multiple sclerosis lesions. J Cell Biochem Suppl. 18D: 143.
14. Gijbels K, Masure S, Carton H, Opdenakker G, (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41: 29-34.
15. Liuzzi GM, Trojano M, Fanelli M, Avolio C, Fasano A, et al. (2002) Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 8: 222-228.
16. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, et al. (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55: 1194-1204.
17. Proost P, Van Damme J, Opdenakker G, (1993) Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 192: 1175-1181.
18. Chandler S, Coates R, Gearing A, Lury J, Wells G, et al. (1995) Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201: 223-226.
19. Asahi M, Wang X, Mori T, Sumii T, Jung JC, et al. (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21: 7724-7732.
20. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, et al. (1999) Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53: 1402-1408.
21. Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, et al. (2003) IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60: 52-57.
22. Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, et al. (2004) Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 127: 259-268.
23. Nakajima K, Hamanoue M, Shimojo M, Takei N, Kohsaka S, (1989) Characterization of microglia isolated from a primary culture of embryonic rat brain by a simplieded method. Biomed Res 10: 411-423.
24. McCarthy KD, de Vellis J, (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902.
25. Deibler GE, Martenson RE, Kies MW, (1972) Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem 2: 139-165.
26. Croall DE, Moffett K, Hatch H, (2002) Casein zymography of calpains using a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-imidazole buffer. Anal Biochem 304: 129-132.
27. McLellan T, (1982) Electrophoresis buffers for polyacrylamide gels at various pH. Anal Biochem 126: 94-99.
28. Liuzzi GM, Latronico T, Fasano A, Carlone G, Riccio P, (2004) Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 10: 290-297.
29. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, et al. (1992) TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576: 203-207.
30. Benveniste EN, (1995) TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function. Faseb J 9: 1577-1584.
31. Leppert D, Waubant E, Galardy R, Bunnett N, Hauser SL, (1995) T-cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 154: 4379-4389.
32. Liuzzi GM, Riccio P, Dal Canto MC, (1995) Release of myelin basic protein-degrading proteolytic activity from microglia and macrophages after infection with Theiler's murine encephalomyelitis virus: comparison between susceptible and resistant mice. J Neuroimmunol 62: 91-102.
33. Liuzzi GM, Mastroianni CM, Latronico T, Mengoni F, Fasano A, et al. (2004b) Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 127: 398-407.
34. Opdenakker G, Van Damme J, (2011) Probing cytokines, chemokines and matrix metalloproteinases towards better immunotherapies of multiple sclerosis. Cytokine Growth Factor Rev 22: 359-65.
35. Guyton MK, Brahmachari S, Das A, Samantaray S, Inoue J, et al. (2009) Inhibition of calpain attenuates encephalitogenicity of MBP-specific T cells. J Neurochem 110: 1895-1907.
36. Guyton MK, Das A, Samantaray S, Wallace GC 4th, Butler JT, et al (2010) Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res 88: 2398-2408.
37. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP, (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74: 111-122.
38. Bartholomé EJ, Van Aelst I, Koyen E, Kiss R, Willems F, et al. (2001) Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta. J Interferon Cytokine Res. 21: 495-501.
39. Benjelloun N, Ménard A, Charriaut-Marlangue C, Mokhtari K, Perron H, et al. (1998) Case report: DNA fragmentation in glial cells in a cerebral biopsy from a multiple sclerosis patient. Cell Mol Biol. 44: 579-83.
40. Dowling P, Shang G, Raval S, Menonna J, Cook S, et al. (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med. 184: 1513-8.
41. Guyton MK, Wingrave JM, Yallapragada AV, Wilford GG, Sribnick EA, et al. (2005) Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. J Neurosci Res 81: 53-61.
42. Suryadevara R, Holter S, Borgmann K, Persidsky R, Labenz-Zink C, et al. (2003) Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 44: 47-56.
43. Mastroianni CM, Liuzzi GM, D'Ettorre G, Lichtner M, Forcina G, et al. (2002) Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV. HIV Clin Trials 3: 310-315.